

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Given Name (First Name) Bruce	2. Surname (Last Name) Leslie	3. Date 25 July 2019
4. Are you the corresponding author?	X Yes No	
5. Manuscript Title SGLT2 Inhibitors: Lack of a Col	mplete History Delays Diagnosis	
6. Manuscript Identifying Number (if M19-1463	you know it)	
Section 2. The Work Up	der Consideration for Publication	
The Work On	der Consideration for Publication	
	cluding but not limited to grants, data monitoring	
any aspect of the submitted work (ind statistical analysis, etc.)? Are there any relevant conflicts of	cluding but not limited to grants, data monitoring interest? Yes X No	
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as	interest? Yes X No ncial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line f	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as	interest? Yes X No ncial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line full report relationships that were present of the submitted voxes in the table to indicate whether you had be compared to the instructions.	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show	interest? Yes X No ncial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line full report relationships that were present of interest? X Yes No	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show the there any relevant conflicts of	interest? Yes X No ncial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line full report relationships that were present of interest? X Yes No 2006-2012	work. we financial relationships (regardless of amo or each entity; add as many lines as you need
Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of Employee of Bristol-Myers Squibb, Employee of Janssen Research and Employee of Pfizer, 2014-2017	interest? Yes X No cial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line fuld report relationships that were present of interest? X Yes No 2006-2012 Development, 2013-2014	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of Employee of Bristol-Myers Squibb, Employee of Janssen Research and	interest? Yes X No cial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line fuld report relationships that were present of interest? X Yes No 2006-2012 Development, 2013-2014	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need
Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of Employee of Bristol-Myers Squibb, Employee of Janssen Research and Employee of Pfizer, 2014-2017	interest? Yes X No cial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line fuld report relationships that were present of interest? X Yes No 2006-2012 Development, 2013-2014	work. Ive financial relationships (regardless of amount of each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of Employee of Bristol-Myers Squibb, Employee of Janssen Research and Employee of Pfizer, 2014-2017 Ownership of stock: Bristol-Myers	interest? Yes X No ncial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line fuld report relationships that were present of interest? X Yes No 2006-2012 Development, 2013-2014 Squibb, Eli Lilly, Pfizer	work. Ive financial relationships (regardless of amount of each entity; add as many lines as you need
any aspect of the submitted work (inc statistical analysis, etc.)? Are there any relevant conflicts of Section 3. Relevant final Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of Employee of Bristol-Myers Squibb, Employee of Janssen Research and Employee of Pfizer, 2014-2017 Ownership of stock: Bristol-Myers	interest? Yes X No cial activities outside the submitted voxes in the table to indicate whether you had described in the instructions. Use one line fuld report relationships that were present of interest? X Yes No 2006-2012 Development, 2013-2014	work. Ive financial relationships (regardless of amoor each entity; add as many lines as you need

United States Patent No. US 8,518,895 B2; Date of Patent: August 27, 2013; Method for Treating Hyponatremia Employing An

SGLT2 Inhibitor and Composition Containing Same. Inventors: Bruce Robert Leslie, Mitchell Halperin





Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
X No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Service 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Generate Disclosure Statement

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Information					
1. Given Name (Fir	rst Name)	2. Surname (La Gerwin	•		3. Date 27 July 20	019
4. Are you the corr	esponding author?	Yes	No			
5. Manuscript Title	e rs: Lack of a Comple	te History Del	ays Diagnosis			
6. Manuscript Ider M19-1463	ntifying Number (if you kr	ow it)				
Section 2.	The Work Under C	onsideration	for Publication			
any aspect of the s statistical analysis, o		but not limited	to grants, data moni			
Are there any rele	evant conflicts of intere	est? Yes	X No			ADD
Section 3.	Relevant financial	activities out	side the submit	ted work.		
of compensation clicking the "Add	he appropriate boxes in with entities as describer with entities as describer +" box. You should reserve evant conflicts of interes	ibed in the inst port relationsh	ructions. Use one	line for each entity;	add as many l	ines as you need by
·						ADD
Section 4.	Intellectual Proper	ty Patents	& Copyrights			
Do you have any	patents, whether plan	ned, pending o	r issued, broadly re	elevant to the work?	Yes	X No



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
X No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Service 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Generate Disclosure Statement

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Taylor 1



Section 1.	Identifying Inform	nation			
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Taylor		3. Date 27-August-2019	
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Bruce Leslie		
5. Manuscript Title SGLT2 Inhibitor Ketoacidosis: Lack of a Complete History Delays Diagnosis					
6. Manuscript Ider	ntifying Number (if you kr	now it)			
Section 2.	The Work Under Co	onsideration for Publ	ication		
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, d	n a third party (government, co ata monitoring board, study de	mmercial, private foundation, etc.) for esign, manuscript preparation,	
Section 3.	Relevant financial	activities outside the	submitted work.		
of compensation clicking the "Add) with entities as descri	ibed in the instructions. Uport relations his we	Ise one line for each entity; a	ationships (regardless of amount add as many lines as you need by nonths prior to publication.	
Section 4.	Intellectual Proper	rty Patents & Copyri	ghts		
Do you have any			roadly relevant to the work?	? ☐ Yes ✓ No	

Taylor 2



Section 5.	Relationships not covered above
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
✓ Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
I was employed a	at Bristol-Myers Squibb (2002-2013), where I worked on dapagliflozin.
On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Taylor report	s that he was employed at Bristol-Myers Squibb (2002-2013), where he worked on dapagliflozin

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Taylor 3